2026-01-04 - Analysis Report
Okay, here's a comprehensive report on Eli Lilly (LLY) based on the data provided, aiming for clarity and simplicity.

**1. Return Rate Comparison and Alpha/Beta Analysis:**

*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company focused on developing and marketing innovative medicines.
*   **Return Comparison:** LLY's cumulative return (281.68%) significantly outperformed the S&P 500 (VOO) return (91.00%).
*   **Divergence:** The divergence between LLY and VOO's cumulative returns is currently 190.7. This is high, as indicated by the relative divergence of 83.9, suggesting LLY's outperformance is near the top end of its historical range compared to VOO.

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2016-2018  | 37.0%  | 14.3%  | 33.0%   | 0.7    | 103.7  |
| 2017-2019  | 36.0%  | 14.7%  | 19.0%   | 0.7    | 117.8  |
| 2018-2020  | 30.0%  | 20.9%  | 10.0%   | 0.7    | 151.4  |
| 2019-2021  | 49.0%  | 20.9%  | 5.0%    | 0.7    | 247.6  |
| 2020-2022  | 59.0%  | 20.9%  | 60.0%   | 0.7    | 328.0  |
| 2021-2023  | 116.0% | 18.0%  | 115.0%  | 0.5    | 522.6  |
| 2022-2024  | 123.0% | 27.0%  | 104.0%  | 0.6    | 692.1  |
| 2023-2025  | 183.0% | 29.9%  | 121.0%  | 0.7    | 963.4  |

*   **Analysis:**

    *   **CAGR:** The Compound Annual Growth Rate (CAGR) has increased dramatically in recent years, with 2023-2025 exhibiting a significant jump.
    *   **MDD:** The Maximum Drawdown (MDD) has fluctuated but remained relatively contained, except for 2022-2025.
    *   **Alpha:**  The Alpha, representing excess return over the market, is strong and has increased significantly in recent periods, indicating that LLY's performance is not solely due to market movements.
    *   **Beta:** The Beta is consistently around 0.7, implying LLY is less volatile than the overall market.
    *   **Cap(B):** Market capitalization has grown exponentially.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 1080.36
*   **Previous Close:** 1074.68 (change of 0.53)
*   **5-day SMA:** 1078.254
*   **20-day SMA:** 1046.905
*   **60-day SMA:** 968.3677

*   **Analysis:** The stock price is above all three moving averages, indicating an upward trend. The 5-day SMA is very close to the closing price, while the 20-day and 60-day SMAs are lower, reinforcing the bullish sentiment.

**3. RSI, PPO, and Market Risk Indicators:**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 76.97 (Approaching overbought territory)
*   **PPO:** -0.1559 (Slightly negative, suggesting price may have recently declined or slowed down)
*   **Hybrid Signal:** Buy 100% (Very Safe)
*   **Recent Divergence Change:** 0.6 (+) (Short-term upward trend)
*   **Expected Return:** 47.3% (Long-term expected excess return compared to the S&P 500)

*   **Analysis:** The RSI suggests the stock is approaching overbought conditions, which could lead to a potential pullback. However, the Hybrid Signal recommends buying, and the MRI suggests a medium investment level. The strong expected return is a positive sign for long-term investors. The positive divergence change in the short term aligns with recent gains.

**4. Recent News & Significant Events:**

*   **Key Headlines:**

    *   GLP-1 pill revolutionizing everything (positive catalyst)
    *   Weight-loss pill pricing and insider filing in focus
    *   Stocks near buy points
    *   Shares purchased by CMH Wealth Management LLC
    *   Future outlook for LLY (10-year perspective)
    *   Stock split candidate in 2026

*   **Analysis:** Recent news is generally positive, focusing on the potential of Eli Lilly's GLP-1 pill for weight loss and the company's strong future outlook. The analyst recommendation and institutional buying (CMH Wealth Management) also support a positive sentiment.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.70 (~Buy)
*   **Number of Opinions:** 27
*   **Target Price:**
    *   Average: 1093.22
    *   High: 1500.00
    *   Low: 770.00

*   **Analysis:** The analyst consensus is firmly bullish, with a Buy rating and an average target price slightly above the current price.  The high target price suggests some analysts see significant further upside potential.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-30 | 6.22 | 17.60 B$   |
| 2025-08-07 | 6.3  | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2025-10-30 | 1.08 | 11.44 B$   |

*   **Analysis:** Both EPS (Earnings Per Share) and Revenue show a clear upward trend, especially from 2024 to 2025. This indicates strong growth in the company's financial performance.

**6. Financial Information (Quarterly):**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-09-30 | $17.60B    | 82.91%        |
| 2025-06-30 | $15.56B    | 84.27%        |
| 2025-03-31 | $12.73B    | 82.53%        |
| 2024-12-31 | $13.53B    | 82.24%        |
| 2024-09-30 | $11.44B    | 81.02%        |

| Quarter    | Equity     | ROE       |
|------------|------------|-----------|
| 2025-09-30 | $23.79B    | 23.46%    |
| 2025-06-30 | $18.27B    | 30.98%    |
| 2025-03-31 | $15.76B    | 17.50%    |
| 2024-12-31 | $14.19B    | 31.07%    |
| 2024-09-30 | $14.24B    | 6.81%     |

*   **Analysis:**
    *   **Revenue & Profit Margin:** Revenue is consistently increasing, indicating strong sales growth.  Profit margins are extremely high, showing excellent operational efficiency.
    *   **Equity & ROE:** Equity is growing, demonstrating the company's increasing value.  ROE (Return on Equity) is fluctuating but remains at healthy levels, indicating efficient use of shareholder equity.

**7. Comprehensive Analysis (Summary):**

Eli Lilly (LLY) presents a compelling investment case based on the provided data:

*   **Strong Performance:** LLY has significantly outperformed the S&P 500, driven by its innovative drug pipeline, especially in the weight loss area.
*   **Positive Momentum:** The stock is in an uptrend, supported by rising moving averages and positive recent divergence.
*   **Solid Financials:** Revenue, profit margins, equity, and ROE all indicate a healthy and growing company.
*   **Bullish Sentiment:** Analyst consensus is strongly bullish, and recent news highlights positive catalysts for future growth.
*   **Potential Overbought:** The RSI suggests the stock may be approaching overbought territory, so potential investors should be mindful of a possible pullback.
*   **Valuation:** While the expected return is high, it is important to consider if the current price already reflects much of the anticipated growth. Further analysis of LLY's financials and future pipeline is recommended.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.